Altimmune Inc
ALT
Company Profile
Business description
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Contact
910 Clopper Road
Suite 201S
GaithersburgMD20878
USAT: +1 240 654-1450
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
59
Altimmune Inc News & Analysis
stocks
2 companies poised to capitalize on the rise of GLP-1 drugs
Why Pfizer and Roche look like top choices for investors in the war to tip the scales.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,312.70 | 88.00 | -0.94% |
| CAC 40 | 8,394.32 | 186.43 | -2.17% |
| DAX 40 | 24,638.00 | 646.26 | -2.56% |
| Dow JONES (US) | 48,838.69 | 139.23 | -0.28% |
| FTSE 100 | 10,780.11 | 130.44 | -1.20% |
| HKSE | 25,998.89 | 60.96 | -0.23% |
| NASDAQ | 22,748.86 | 80.64 | 0.36% |
| Nikkei 225 | 56,727.27 | 1,329.97 | -2.29% |
| NZX 50 Index | 13,620.41 | 102.56 | -0.75% |
| S&P 500 | 6,875.63 | 3.25 | -0.05% |
| S&P/ASX 200 | 9,095.40 | 72.70 | -0.79% |
| SSE Composite Index | 4,179.11 | 3.48 | -0.08% |